Dr. Richard King was born and grew up in New Zealand, where he attended Otago and Victoria Universities as an undergraduate. He graduated from the University of Dundee Medical School in Scotland and trained in anesthesia in Southern Africa, where he received his board certification. Dr. King came to the United States in 1985, and after completing a fellowship in regional anesthesia at Hospital for Special Surgery, joined the Attending Staff.
Dr. King’s main interests include regional anesthesia for orthopaedic surgery, the treatment of acute postoperative pain, and the prevention of postoperative nausea and vomiting.
Dr. King has chaired the departmental Quality Assurance and Educational Committees and retains a special interest in the training of residents and fellows in regional anesthesia.
One of the goals of Hospital for Special Surgery (HSS) is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.
As part of the disclosure process, this website lists physician collaborations with outside companies if payments were received during the prior year, or if the HSS physician currently receives payment. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.
As of May 16, 2013, Dr. King reported no financial interest relationships with healthcare industry.
By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, HSS’ Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.